Stem Cell Cardiology explores the use of regenerative therapies to repair damaged myocardium, restore function and modify the progression of chronic heart disease. As interest in biological repair accelerates, many clinicians and researchers seek deeper understanding of Stem Cell Cardiology when attending innovation tracks at a cardiology conference. Because cellular therapeutics represent a rapidly evolving frontier, this session offers a detailed examination of mechanisms, trial evidence, practical barriers and future opportunities in cardiac regenerative therapy.

The session begins with an overview of myocardial injury and limited endogenous repair, explaining how cardiomyocyte loss after myocardial infarction or chronic cardiomyopathy results in scar formation, remodeling and progressive heart-failure symptoms. Participants explore how stem-cell–based approaches aim to counteract these processes through replacement of damaged cells, paracrine signaling, immunomodulation and promotion of angiogenesis. Various cell types—including mesenchymal stem cells, cardiac progenitor cells, induced pluripotent stem cells and skeletal myoblasts—are examined for their regenerative potential, advantages and biologic limitations.

Preclinical findings and translational models are reviewed to illustrate how these therapies have shown improvements in perfusion, contractility and scar reduction. The session then transitions into human clinical trial data, highlighting both promising results and inconsistent outcomes. Participants will explore challenges such as cell survival, retention, delivery methods and variability of endpoints across trials. These insights help clinicians interpret the evidence critically while recognising the complexity of translating basic science into meaningful clinical improvements.

Delivery techniques form a major part of the discussion. Attendees examine catheter-based injections, transendocardial delivery, epicardial placement, intracoronary infusion and emerging bioengineered scaffolds that enhance cell viability. The session explains how imaging guidance—including MRI, CT and 3D echo—supports precise delivery and monitoring of therapeutic impact.

Safety considerations include arrhythmia risk, immune response, tumorigenicity and long-term tissue integration. Ethical aspects of stem-cell sourcing, clinical trial design, manufacturing standards and regulatory oversight are addressed to ensure responsible implementation.

Future directions include gene-edited stem cells, tissue-engineered patches, exosome-based therapy, CRISPR-enabled cardiomyocyte regeneration and hybrid biologic-device approaches. Participants review how AI may enhance patient selection, predict treatment response and refine post-therapy monitoring. The session also explores potential integration of regenerative therapies with existing heart-failure treatments, ventricular assist devices and post-MI care pathways.

By the end of this session, clinicians will understand the scientific foundations, limitations and future promise of stem-cell–based cardiac repair, gaining a realistic appreciation of how regenerative medicine may reshape long-term outcomes for patients with advanced heart disease.